Centers for Disease Control and Prevention

Demographics of Patients Receiving TPOXX for Treatment of Monkeypox

Updated August 22, 2022

CDC, in partnership with FDA, has made it easier for healthcare providers to provide tecovirimat (TPOXX) treatment to patients with monkeypox under an expanded access Investigational New Drug (EA-IND) protocol. As of August 18, 2022, CDC has received and abstracted data from forms submitted on 288 patients. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting paperwork to CDC. The table below shows the demographics of these 288 patients who have received TPOXX and whose data has been analyzed.

Demographics	N (%)*
Age (N=288)	37.0 (median)
	20-76 (range)
Missing	1 (N/A)
Sex at birth (N=288)	
Male	281 (98.9%)
Female	3 (1.1%)
Not reported	4 (N/A)
Race and ethnicity (N=288)	
Asian, non-Hispanic	8 (3.1%)
Black, non-Hispanic	40 (15.6%)
White, non-Hispanic	103 (40.2%)
Hispanic	90 (35.2%)
Unknown Race, non-Hispanic	6 (2.3%)
Multiple Races, non-Hispanic	5 (2.0%)
Other, non-Hispanic	4 (1.6%)
Missing	32 (N/A)

Among the 288 who have baseline IND paperwork, the median age was 37 with a range of 20 to 76 years old; white non-Hispanics were the largest represented racial and ethnic group. Among those that reported a sex at birth, 98.9% are male.

CDC has not received forms for every patient treated with TPOXX. There may be a lag in forms being submitted, so forms for patients treated recently may be more likely to be missing. Some sections of the submitted forms may also be incomplete. Therefore, these data may not reflect the overall population of patients who have received TPOXX.

As of August 18, 2022, CDC has received more than 400 patient intake forms and has abstracted forms for 288 individuals and clinical outcome forms for 287 individuals. Of the 287 patients with outcome forms, 94 included data during and post-treatment, 172 included data only during treatment, and 21 included data only post-treatment.

Page last reviewed: August 22, 2022